| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Clinical Trial |
The treatment of community-acquired pneumonia is empirical in most cases and must cover a wide range of potential pathogens, such as Streptococcus pneumoniae, including penicillin-resistant strains, Haemophilus influenzae and intracellular microorganisms. The objective of this double-blind, randomized, parallel group study was to compare the efficacy and safety of sparfloxacin (400 mg loading dose, followed by 200 mg o.d.) with that of oral amoxycillin-clavulanic acid (500/125 mg t.i.d.) or oral erythromycin (1 g b.i.d.), during 7-14 days in 808 patients with confirmed community-acquired pneumonia. The overall success rates for sparfloxacin (87%), amoxycillin-clavulanic acid (80%) and erythromycin (85%) were similar in evaluable patients, and the equivalence hypothesis used for the statistical analysis showed at least an equivalent efficacy for the three antibiotics tested. The analysis of microbiologically documented infections (40% of the patients) showed that overall success rates were similar for S. pneumoniae and H. influenzae infections. Treatment withdrawal was necessary in 3.5, 2.5 and 7.7% of the patients treated with sparfloxacin, amoxycillin-clavulanic acid and erythromycin, respectively. This study indicates that sparfloxacin was at least as effective as amoxycillin-clavulanic acid or erythromycin in the treatment of mild-to-moderate community-acquired pneumonia and that the adverse effects were similar in the three groups.
This article has been cited by other articles:
|
|
 |
|
  D. Shefet, E. Robenshtok, M. Paul, and L. Leibovici Empirical Atypical Coverage for Inpatients With Community-Acquired Pneumonia: Systematic Review of Randomized Controlled Trials Arch Intern Med, September 26, 2005; 165(17): 1992 - 2000. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D Mills, M. R Oehley, and B. Arrol Effectiveness of {beta} lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis BMJ, February 26, 2005; 330(7489): 456. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Singer, I. Harding, M. R. Jacobs, and D. H. Jaffe Impact of antimicrobial resistance on health outcomes in the out-patient treatment of adult community-acquired pneumonia: a probability model J. Antimicrob. Chemother., May 1, 2003; 51(5): 1269 - 1282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ortqvist Treatment of community-acquired lower respiratory tract infections in adults Eur. Respir. J., July 1, 2002; 20(36_suppl): 40S - 53s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 BTS Guidelines for the Management of Community Acquired Pneumonia in Adults Thorax, December 1, 2001; 56(90004): iv1 - 64. [Full Text] [PDF]
|
|
|
|
|
|
A. Lubasch, R. Erbes, H. Mauch, and H. Lode Sparfloxacin in the treatment of drug resistant tuberculosis or intolerance of first line therapy Eur. Respir. J., April 1, 2001; 17(4): 641 - 646. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Petitpretz, P. Arvis, M. Marel, J. Moita, and J. Urueta Oral Moxifloxacin vs High-Dosage Amoxicillin in the Treatment of Mild-to-Moderate, Community-Acquired, Suspected Pneumococcal Pneumonia in Adults Chest, January 1, 2001; 119(1): 185 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Cubbon and R. G. Masterton New quinolones--a fresh answer to the pneumococcus J. Antimicrob. Chemother., December 1, 2000; 46(6): 869 - 872. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
